Drug intelligence / Profile preview

Alzant

Development stage: Unknown
Lead developer: Bilim Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Alzant is a branded generic pharmaceutical product containing memantine hydrochloride, developed and manufactured by Bilim Pharmaceuticals. It functions as a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. The drug is designed to treat moderate to severe dementia associated with Alzheimer's disease by blocking the overstimulation of NMDA receptors by glutamate, which is thought to contribute to the neurodegeneration seen in the condition. By normalizing glutamatergic neurotransmission, Alzant helps to improve cognitive function and daily living activities in patients. It is primarily marketed in Turkey and is available in various tablet strengths.

Brand names: Alzant
Other names: memantinememantine hydrochloride

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on Alzant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alzant.

Explore the full profile